Use casesClinical Trial Supply
Protect comparator continuity. Reduce mid-trial disruption.
Comparator sourcing decisions increasingly need justifying, to sponsors, procurement and finance. MedSupply Intelligence gives clinical trial supply teams the market evidence to decide which comparators justify forward-buy investment and which formats carry hidden risk.
Who this is for
Comparator sourcing, clinical supply and supply assurance teams at clinical trial supply organisations, and the sponsors they support.
The challenge
Supply issues rarely stay in one format.
When a manufacturer exits a market, loses capacity or has a recall, pressure spreads across presentations. A format with no supply alerts of its own can still depend on an active ingredient that is under pressure elsewhere.
Trials run on fixed timelines, so by the time that reaches your SKU, options have narrowed.
The format looked stable. The molecule wasn't.
How MedSupply Intelligence helps
Evidence, not instinct.
The question is no longer just “can we source it?” but “which molecules justify the investment, and what does the market say?” MedSupply Intelligence brings supply pressure, pricing movement and active-ingredient risk together across your comparator portfolio in one view.
Compare our productsFive decisions. Documented evidence.
Validate comparator inventory decisions before capital is committedSupply assurance
Supply assurance programmes need evidence-based stock holding. Understand which molecules carry structural risk and which formats are most exposed before committing to forward-buy.
Pre-ordering backed by documented supply risk is not speculation. It is risk-proportionate procurement.
Supports
- Which comparators justify forward-buy
- Inventory depth
- Supply assurance commitments
See active-ingredient stress before formats failMolecule risk
Pressure at the active-ingredient level is often invisible at the product or format level. Seeing it earlier helps avoid reactive substitution and mid-study sourcing emergencies.
Supports
- Substitution planning
- Sponsor escalation
- Format selection
Monitor comparator portfolios, not individual productsPortfolio monitoring
Teams manage portfolios across studies, therapy areas and supply horizons. See supply and pricing pressure across the whole comparator list in one view, rather than checking dozens of SKUs one by one.
Supports
- Prioritising attention
- Parallel sourcing strategies
- Less manual review
Validate forecast exposure before committing capitalProcurement confidence
Forecast demand is only useful if supply remains available. Market evidence helps test whether forecast comparator demand is resilient or exposed.
Supports
- Forward-buy positions
- Pre-order financing
- Procurement timing
- Internal approvals
Support sponsor decisions with structured market evidenceSponsor confidence
Sponsors are making study design and supply strategy decisions based on comparator availability. Structured evidence strengthens those conversations, from feasibility through ongoing supply assurance reporting.
Sponsors are not just buying comparator supply. They are buying confidence that it will be there when the trial needs it.
Supports
- Sponsor discussions
- Bid and RFP responses
- Supply assurance design
MedSupply Intelligence brings together supply, availability, pricing and risk signals to give earlier visibility of emerging market pressure and changing conditions.
See the supply picture across your comparator portfolio.